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ABSTRACT 
Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea 
and weakness symptoms. Around 12 percent of Americans, 9 percent of Asians experiences migraine and the prevalence is highest among South 
Koreans (22.3%). The outcome of chronic migraine treatment can be quite disheartening, causing patients to feel out of options who have tried 
multiple treatments with no results. Poor efficacy, tolerability and safety of migraine preventive therapy in clinical practice lead to poor compliance 
and failure of therapy. The mean change in number or frequency of headache is considered as the outcome measure of migraine prevention therapy. 
Upon comparing all migraine prevention therapy, the Fremanezumab, Eptinezumab, Galcanezumab and Erenumab were considered as the front 
runner in controlling the severity and frequency of migraine. Among these drugs, Erenumab was most effective in controlling the frequency of 
migraine episodes as it produces more than 50 percent reduction in the mean number of monthly migraine days (MMD) over week 9-week 12. In 
addition to drug therapy, adequate rest, balanced diet, yoga and meditation will help patients to get rid of migraine severity. A multi-dimensional 
approach is essential for better control over migraine symptoms.  
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INTRODUCTION 
Migraine is an extremely usual, persistent, and normally genetically-
related neurovascular disorder which occurs at irregular intervals 
[1]. It is a weakening brain disorder impacting approximately fifteen 
percent of the world population. Generally, migraine attacks 
comprise of severe headaches which accompany by a group of 
symptoms, lasting for four to seventy-two hours, for instance, 
nausea, vomiting, photo-and phonophobia [2]. As a major cause of 
neurological disability worldwide and due to its nature, it is 
undoubtedly having a significant effect on society [3-5]. In addition, 
migraine can be categorized into episodic migraine and chronic 
migraine. The most common form of migraine is episodic migraine, 
has an attack of headache happening for less than 15 d monthly [3]. 
As a multifactorial genetic disorder, migraine has two mechanisms, 
which are the neuronal and vascular pathway that includes several 
dozens of gene variants with minimal effect size [4]. There are 
around twenty to thirty percent of migraineurs are affected by 
short-term focal neurologic symptoms, which can occur before or 
during the headache and it is called aura [5]. The frequency, 
duration, and intensity of the migraine attack can be different among 
individuals. The occurrence of temporary disability due to migraine 
attack creates a significant impact to the migraine patients’ work 
and activities lead to impairment in productivity and quality of life of 
the patients [1].  
The data extracted for this review is mainly on the antimigraine 
drugs used in the treatment of various migraine disorders. The main 
source of data used is PubMed, Nvivo, Mendeley, Evernote, CiteUlike, 
Biohunter, Delvehealth, Scicurve, and Google Scholar, etc. Articles on 
complementary therapy on migraine disorder and animal studies 
were excluded. The antimigraine drugs included in our studies are 
those that were approved by US-FDA, as according to Centre Watch. 
All the authors independently extracted the relevant information 
from studies that fulfilled our inclusion criteria and any 
disagreements were resolved with consensus. The information 
extracted included the trial phase, region, conditions of subjects and 
the outcome measures. This information was gathered and 
summarized into paragraphs, introducing each antimigraine drug 
comprehensively. 
Epidemiology 
As a neurovascular disease, migraine is currently being considered 
as a severe and prevalent health issue. To be more precise, it has 
become the sixth-leading cause disability globally and the 
third-leading cause of disability in people of age less than 50-year-
old [6-9]. 
Migraine has affected different populations, with the highest 
incidence in Europe and North America (13%), followed by Asia 
(9%) [10]. Besides, it has been shown through a recent study 
regarding the headache disorders in India, which outlined 
individuals suffering from various headaches, of which 26% of them 
suffer from migraine [11]. Furthermore, the 2010 Global Burden of 
Disease Study had presented that the worldwide prevalence of 
migraine was 14.7%, which was slightly lower as compared to the 
incidence of tension-type headache (20.1%) [12-14]. In 2013, the 
same study was being conducted and revealed that neurological 
disorders had contributed to over half of all years lost to disability 
[10-16]. In 2015, the study reported that migraine was considered 
one of the eight chronic diseases which influenced more than 10% of 
the global population [17]. Gender wise, it had a greater impact on 
women compared to men, with prevalence of 17% and 6% 
respectively, resulting to a remarkable socioeconomic burden to the 
society. Migraine was then proved to be the second-highest cause of 
years lived with disability globally in the 2016 Global Burden of 
Disease study [18]. 
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Migraine also related to the people’s socioeconomic burden, with 
respect to both standard of living and lost efficacy [19]. This is 
supported by previous studies, which indicated that about 9 out of 
10 migraine patients are functionally affected during an attack, 
approximately half of them are gravely impaired and in need of bed 
rest. It has also been reported that those with migraine are only 
about half as productive at work compared to those without [8, 20]. 
Furthermore, the burden of migraine is higher in part-timers or 
those who are jobless, has low socioeconomic status, and no 
government insurance. These populations are presumably to have 
limited access to health care and treatment for their headaches. In 
addition, these people are more likely to be exposed to triggers and 
other factors that can aggravate headache. Therefore, this is 
progressively relevant as the managements of migraine and other 
severe headaches move from symptom-based, non-specific therapies 
to more specific, individualized, and cost-effective treatments such 
as the new anti-calcitonin gene-related peptide (anti-CGRP) 
antibodies. It is crucial to understand the distribution of headache in 
specific segments of the population as this allows the treatments to 
be accessible to those most in need [21]. The current conventional 
drugs control the severity of migraine at a certain level; however, no 
complete salvage from the recurrent migraine attacks. A novel 
antimigraine therapy is needed to control the severity and recurrent 
attacks, and also has the least side-effects. Hence, a review was 
carried out to compare the mechanism, efficacy and safety of 
antimigraine drugs that indicated for the treatment of migraine 
disorder. 
Management 
Migraine is generally managed with a different class of drugs, 
namely non-steroidal anti-inflammatory drugs (NSAID), 5-hydroxy 
tryptamine (5HT)-agonists, ergot preparations, and specific drugs 
targeting the receptors. Prophylactic treatment choices for 
migraines include drugs developed for diseases other than 
migraines such as depression, epilepsy and hypertension [22]. In the 
past ten years, inhibiting CGRP has appeared to be a possible 
mechanism to prevent migraine attacks. This is supported by recent 
evidence suggesting that dysfunctional activation of the 
trigeminovascular system involving CGRP is implied in migraine 
pathogenesis [22-25]. The drugs which are commonly used in 
migraine are discussed comprehensively below emphasizing their 
mechanism of action, efficacy and safety in migraine prevention or 
control. The summary of the efficacy and safety of newer drugs that 
recently approved for the treatment of migraine are compared and 
presented in table 1. 
 
Table 1: Comparison of efficacy and safety of newer drugs that approved by US-FDA for the treatment of migraine disorder 
Author name Title of the article Study design Outcome Efficacy Safety 
CGRP antagonist 
1. Fremanezumab 
Dodick et al., 
[49] 
Effect of fremanezumab 
compared with placebo 
for prevention of episodic 





phase 3 study 
Mean change 
from baseline in 




week period after 
the first dose 
1.3-to 1.5-day 
reduction in the 
mean number of 
monthly migraine 
days over a 12-
week period 
Injection site-related pain 
Bigal et al., 
[50] 
Safety, tolerability, and 
efficacy of TEV-48125 for 
preventive treatment of 
chronic migraine: A 
multicentre, randomised, 
double-blind, placebo-







phase 2b study 
Mean change in 
the number of 
headache-hours 
675/225 mg group: 
–59·84 h 
900 mg 
group: –67·51 h 
Injection site-related pain 
Cohen et al., 
[51] 
Fremanezumab as an add-
on treatment for patients 






Mean change in 
migraine days 
 
Total reduction in 
migraine days for 
the duration of the 
study was 12.4 
 
Injection site-related pain 
2. Eptinezumab 
Dodick et al., 
[52] 
Safety and efficacy of ALD 
403 for the prevention of 
frequent episodic 
migraine: a randomised, 
double-blind, placebo-
controlled, exploratory 





of-concept phase 2 
trial of an 
intravenous dose of 
ALD 403 at 26 









43 (52%) of 82 patients in the 
placebo group and 46 (57%) 
of 81 in the ALD403 group 
experience adverse events. 
Patients who received 
ALD403 had pyelonephritis; 
One patient had four serious 
adverse events, which are 
chest pain, transient 
ischaemic attack, conversion 
disorder, and dyspnoea. 
Dodick, et al., 
[53]  
Eptinezumab for 
prevention of chronic 
migraine: A randomized 








MHD at 5-8 w: 
Active (-5.6 MHDs) 
vs placebo (-4.6 
MHlanfDs) 
Mild to moderate adverse 
events occurred in 57% of 
patients in the eptinezumab 
group and 52% in the placebo 
group. 6 patients in the 
placebo group vs 7 patients in 
the eptinezumab group 
experience upper respiratory 
tract;  
4 patients vs 1 patient 
experience urinary tract 
infections; fatigue (3 vs3), 
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back pain (4 vs 3), arthralgia 
(4 vs 1), and nausea (2 vs 3). 
No infusion reactions were 
reported 2 patients in the 
eptinezumab group and 1 
patient in the placebo group 




et al., [58] 
Preventive effects of 
galcanezumab in adult 
patients with episodic or 
chronic migraine are 
persistent: data from the 
phase 3, randomized, 
double-blind, placebo-
controlled EVOLVE-1, 










At month 1, 20% of 
patients had a 
sustained response 
of ≥50% reduction 
of MHDs over 
6 months; about 




Injection site-related pain 
Skljarevski et 
al., [57] 
Efficacy and safety of 
galcanezumab for the 
prevention of episodic 
migraine: Results of the 






multicenter, phase 3 
study at 109 study 






120 mg: -4.3 MHDs 
240 mg: -4.2 MHDs 
Injection site-related pain 
Skljarevski et 
al., [68] 
Effect of Different Doses of 
Galcanezumab vs Placebo 
for Episodic Migraine 





phase 2b study in 
clinics of 37 
licensed physicians 





120 mg: −4.8 MHDs Injection site-related pain 
CGRP-Receptor Antagonist 
1. Erenumab 
Dodick et al., 
[59] 
ARISE: A Phase 3 
randomized trial of 










(EM), had 4-15 
MMD with or 
without aura for at 




days (MMD) over 
Month 3 of study. 
 
70 mg SC monthly 
vs placebo 
(p<0.001) 
-2.9 d change in 
MMD from baseline 
Most common AE-Upper 
respiratory tract infection 
Reuter et al., 
[62] 
Efficacy and tolerability of 
erenumab in patients with 












controlled, phase 3b 
study 
Criteria: 246 
participants with a 
history of EM with 
or without aura for 
at least 12 mo, had 
migraine for 
average of 4-14 d 
per months over 3 








in the mean 
number of MMD 
over Week 9-
Week 12. 
40 mg (via two 
divided 70 mg 
injections) SC 
monthly vs placebo 
36/119 of 
erenumab group 
had ≥50% reduction 
in mean number of 
MMD vs 17/124 of 
placebo group had 
≥50% reduction in 
mean number of 
MMD 
Most common AE–pain at the 
injection site 
Goadsby et al., 
[61] 
A Controlled Trial of 






controlled, phase 3 
study 
Criteria: 955 
Change in the 
mean number of 
MMD over Month 
4–Month 6 
70 mg SC monthly, 
140 mg SC monthly 
vs placebo (p<0.001 
for each dose vs 
placebo) 
70 mg shows-3.2 d 
Most common AE-
Nasopharyngitis 
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participants with a 
history of migraine 
with or without 
aura for at least 12 
mo prior to 
screening, had at 
least 4-15 migraine 
days per months 
and<15 headache 
days per month on 






reporting with an 
electronic diary in 
baseline phase 
change in MMD 
140 mg shows-3.7 d 
change in MMD 
Tepper et al., 
[63] 
Safety and efficacy of 
erenumab for preventive 
treatment of chronic 
migraine: a randomized, 
double-blind, placebo-




controlled, phase 2 
study 
Criteria: 667 
participants with a 
history of chronic 
migraine, had 15 or 
more headache days 
per month, of which 
8 or more of those 
days were migraine 
days, demonstrated 
at least 80% 
adherence to 
reporting with an 
electronic diary in 
baseline phase 
Change in MMD 
in week 9-week 
12 
70 mg SC monthly, 
140 mg SC monthly 
vs placebo 
(p<0.0001) 
Both 70 mg and 140 
mg shows-6.6 d 
change in MMD 
 
Most common AEs: Injection-
site pain, muscle spasm 
 
Mechanism of action 
a) Non-steroidal anti-inflammatory drugs  
Acetaminophen and NSAIDs which possess analgesic and anti-
inflammatory actions in migraine by inhibiting the enzyme 
cyclooxygenase (COX) to reduce prostaglandin synthesis from 
arachidonic acid [26]. There are two cyclooxygenase enzymes which 
are COX-1 is widely expressed in gastrointestinal tract, whereas 
COX-2 is widely predominated at sites of inflammation [27]. Aspirin 
inactivates COX-1 irreversibly and inhibit the production of 
prostaglandin (PGH2) where it acts as a primary precursor of 
thromboxane A2. Aspirin interacts with the amino acid Arg120 
which result obstructing of the accessibility of arachidonic acid to 
the Tyr385 hydrophobic channel at catalytic site [28].  
b) 5-hydroxy tryptamine (5HT)-agonist 
In the 1990s, the emergence of the selective 5-HT1B and 5-HT1D 
receptors agonists was a significant advancement for the acute 
management of migraine. Triptans exhibit antimigraine effects 
through cranial vasoconstriction and by inhibition of CGRP in the 
perivascular nerve terminals, subsequently reducing the activation 
of trigeminal nociceptors [29-31]. A few examples of the triptans 
include zolmitriptan, rizatriptan, and naratriptan. 
c) Ergots 
According to the vascular theories of migraine, the ergot alkaloids as 
vasoconstrictors were turned into one of the earliest approaches 
towards migraine attacks [32]. Antimigraine drugs introduced to the 
market were ergotamine (E) tartrate as the first pure ergot alkaloid 
and dihydroergotamine (DHE) [33]. Ergots are indicated for 
migraines that also present with a long period and infrequent 
headaches and to patients who are likely to adhere with dosing 
restrictions. E and DHE once remained as the only available acute 
specific antimigraine treatments until sumatriptans were developed 
in 1980s. The ergots have high selectivity for various receptors, such 
as dopamine, noradrenaline and serotonin (5-hydroxytryptamine). E 
and DHE interact with 5-HT1A, 1B, 1D, 1F, 2A, 2C, 3, 4 subtypes.  
d) Others drugs 
Botulinum toxin A (BoNT-A), due to its healing properties and its 
ability to alleviate pain, an increasing number of studies have been 
carried out for the past ten years to investigate the efficiency of 
BoNT-A in treating migraines. Animal and human studies have 
revealed that BoNT-A inhibits the release of the neurotransmitters 
glutamate A, calcitonin gene-related peptide and Substance-P, which 
are important mediators of inflammatory pain. Hence, nociceptive 
signals reaching the central system are minimized. BoNT-A is 
administered peripherally in the form of injections to the head or 
neck [32]. 
Specific management 
The specific management of migraine includes CGRP antagonists and 
its receptor antagonists, both are considered simultaneously in some 
cases depends on the severity of the condition. 
Calcitonin gene-related peptide antagonists 
a) Fremanezumab 
Fremanezumab, also known as Ajovy is the second drug after 
erenumab (Aimovig) to be approved by the FDA for the preventive 
treatment of migraines. Engineered by recombinant DNA 
technology, Fremanezumab is a fully-humanized monoclonal 
antibody. It has a strong affinity for CGRP ligand, a neuropeptide that 
is strongly implicated in migraine pathophysiology. This antibody is 
made up of 1324 amino acids and has a molecular weight of 
approximately 148 kDa. Being highly specific, tolerable and safe, 
Sivanandy et al. 
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Fremanezumab has proved to be an ideal drug development for 
migraines. Goadsby et al., found direct evidence that the 
prophylactic effect of CGRP-mAbs is achieved mainly through their 
ability to prevent the activation of peripheral trigeminovascular 
neurons of the Aδ type by events that lead to cerebral release of 
CGRP during a migraine headache [34, 35]. While erenumab blocks 
CGRP receptor, fremanezumab binds to the CGRP molecule and 
blocks its attachment to the CGRP receptor. Fremanezumab has an 
estimated half-life of approximately 31 d. Two subcutaneous dosing 
options of Ajovy exist which are a monthly dose of 225 mg or 675 
mg to be administered every 3 mo. In clinical trials, hypersensitivity 
reactions including rash and pruritus were reported at injection 
sites within hours to one month after administration. 
b) Eptinezumab 
Eptinezumab, ALD403 is a fully-humanized IgG1 antibody that binds 
specifically and selectively to both alpha and beta forms of the 
human CGRP. ALD403 also binds potently (Kd<20 pM) to human 
CGRP [36]. 
c) Galcanezumab 
One of the recently approved drugs for migraine prevention called 
galcanezumab-gnlm, also known as LY2951742, is an entirely 
humanized monoclonal antibody which potently and selectively 
binds to CGRP ligand and blocks its binding to the receptor, 
hindering CGRP-mediated vasodilation effects [36, 37]. 
Calcitonin gene-related peptide receptor antagonists 
a) Erenumab 
Erenumab is the first FDA-approved GCRP-receptor monoclonal 
antibody specifically developed for the management of migraines 
[38]. It is formerly known as AMG334, due to its nature as a fully 
human monoclonal antibody, it specifically attaches to CGRP 
receptor. Attachment sites of this receptor is closely related to 
receptor activity-modifying protein 1 (RAMP1) complex and 
calcitonin receptor-like receptor (CLR). Through this binding, the 
biological activities of CGRP are blocked with an IC50 (2.3±0.9 nM) 
[39]. Erenumab is 5000-fold more specific for CGRP receptor as 
compared to any other human calcitonin family receptors. 
Erenumab is considered as a very large molecule where its 
molecular weight is about 150.000 kDA. In the contrary, small 
molecule of CGRP receptor antagonists have molecular weight of less 
than 500 kDA, making it possible to enter the central nervous 
system (CNS) [40]. Due to its large molecular size, it poses a low risk 
of penetration into the blood-brain barrier (BBB) that can result in 
adverse reactions associated with CNS. According to Eftekhari et al., 
[41] erenumab has mode of action outside of BBB, specifically at 
trigeminal ganglion. Site of expression of CGRP are in neurons of 
greater sizes, specifically Aδ neurons as well as the cells of satellite 
glial. Meanwhile, CGRP receptors are dispersed in c-fiber neurons of 
relatively smaller diameter. Inhibitory action of erenumab on 
activation of Aδ results in the preventive effect in migraines. 
Erenumab possess half-life of 26 d, and this explains the need for 
drug administration to be done only once a month [42]. Route of 
administration of this drug is through subcutaneous injection thus 
having its primary metabolism handled by the reticuloendothelial 
system. It is found that erenumab is not eliminated via hepatic, renal 
or biliary process, which lowers the risk of drug-drug interactions by 
not competing with other drugs via these excretion pathways. 
Through various studies, erenumab is considered to be highly potent 
in inhibiting the capsaicin-induced dermal blood flow (CIDBF) [38]. 
Efficacy 
The efficacy of recently marketed antimigraine drugs was critically 
analyzed using the reduction in pain intensity and the number of 
headache-free days. The details are presented below. 
a) Non-steroidal anti-inflammatory drugs 
Aspirin is well-known in the treatment of migraine. A systematic 
Cochrane review discovered that a single dose of 1g of aspirin 
relieves headache in 52% of attacks and 32% for placebo at 2 h, 
whereas 24% shown free of pain at 2 h compared to 11% for 
placebo. At a dose of 1g acetaminophen alone had high efficiency 
while at a dose of 650 mg, acetaminophen was not better than 
placebo [27]. Acetaminophen, other NSAIDs and aspirin are the most 
widely used drugs for migraine attack. Nonetheless, many 
randomized controlled trails proved that the efficacy of 
acetaminophen is slightly lower than other NSAIDs for a migraine 
attack. 
b) 5-hydroxy tryptamine (5HT)-agonists 
Oral sumatriptan 50 mg and eletriptan 40 mg are the most 
advantageous as a first-line specific acute migraine therapy, while 
subcutaneous sumatriptan 6 mg is the most effective currently 
marketed drug [43]. Zolmitriptan has an efficacy of 62% at 2 h and 
up to 78% within 4 h on a regular dose 2.5 to 5 mg orally or as 
intranasal spray. One of the new delivery methods for an aged acute 
migraine therapy is Zecuity® which is a battery-powered, 
transdermal sumatriptan patch considered more suitable for 
migraine headaches and cluster headaches [44]. 
c) Ergots 
Oral formulations of ergot are poorly absorbed due to extensive 
first-pass metabolism with nausea as its main side effect, while its 
rectal form shows higher efficacy where relatively higher plasma 
levels are observed. Rectal formulation of ergot is thus 
recommended for patients with early onset of migraine with severe 
nausea and vomiting. DHE are currently available as intravenous, 
intramuscular, subcutaneous and intranasal formulations. Among 
ergot alkaloids, DHE is at an advantage as it is marketed with various 
administration possibilities, is relatively a weaker vasoconstrictor 
[45] and has longer half-life. Due to its longer half-life, it has a low 
risk of medication overuse [46] as well as lesser side effects. Usage 
of ergots as antimigraine should be limited only to younger patients 
who respond poorly to other treatments [47]. 
d) Others drugs 
Similar to other preventive migraine treatments, it has been found 
that the advantageous effects of BoNT-A could be noticed mostly in 
2nd and 3rd months of post-treatment period. This is in accordance 
with findings which state that it takes up to 3 w for botulinum toxin 
to achieve its maximum efficiency. In patients suffering from chronic 
migraine, it can be noted that BoNT-A reduces the number of 
migraine days by 2 d over a period of one month. Due to the 
unavailability of high-quality evidence, it remains unclear as to 
whether BoNT-A is effective in preventing episodic migraine [48]. 
Specific management 
Calcitonin gene-related peptide antagonists 
a) Fremanezumab 
Dodick et al., enrolled 875 participants in a phase 3, double-blind, 
placebo-controlled, parallel group study whereby fremanezumab was 
administered either monthly or a higher dose was given only once 
while others received placebo. The primary end point being 
investigated in this study was the mean change from baseline in the 
mean number of MMD, 12 w after the first injection. Based on the 
findings, 12 w after receiving the first dose, a reduction from 8.9 to 4.9 
MMD was observed for the monthly fremanezumab dosing group. 
Patients received a single higher dose of fremanezumab showed a 9.2 
to 5.3 MMD reduction while placebo group showed a decrease from 
9.1 to 6.5 d. The MMD declined by at least half in 47.7% of patients 
who were injected with fremanezumab monthly and 44.4% those who 
received the single higher dose of fremanezumab as compared with 
27.9% for the placebo group. This study also concluded that among 
patients with episodic migraine, subcutaneous fremanezumab reduced 
the MMD by 1.3 to 1.5 d [49]. In another phase 2b, double-blind, 
double-dummy, placebo-controlled, parallel-group study conducted by 
Bigal et al., participants were enrolled to receive 675/225 mg 
fremanezumab, 900 mg fremanezumab or placebo. During weeks 9–
12, findings showed that in the 675/225 mg group, the mean change 
from baseline in the number of headache-hours was −59·84 while in 
the 900 mg group, the change was −67·51 h and −37·10 h in the 
placebo group. A 38% decrease in the headache-hours was observed 
for those who received 675/225 mg dose of fremanezumab, while in 
Sivanandy et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 7, 1-9 
6 
the 900 mg group, headache-hours decreased by 43% compared to 
only 22% in the placebo group [50]. In two randomized placebo-
controlled studies carried by Cohen et al., the total decline in migraine 
days was 12.4 for fremanezumab and 7.4 for placebo during the study 
period, in patients who were already on other migraine preventive 
medications. Decreases in moderate/severe headache days were also 
observed. Similarly, the number of days where acute medication was 
used for headaches decreased compared to placebo. The study 
concluded that in patients who were already on anti-migraine therapy, 
fremanezumab significantly reduced the MMD as well as moderate to 
severe headache days, and days whereby acute medication was used. 
Hence, the efficacy of fremanezumab as a complementary therapy to 
other migraine preventive medications was hence validated by this 
study [51]. 
b) Eptinezumab 
Dodick et al., in their randomized, double-blind, placebo-controlled, 
exploratory phase 2 trial in migraine patient population stated due to 
its momentary and mild or moderate-severe adverse effects, 
Eptinezumab (ALD403) was normally safe and well-tolerated. On 
week 5-8, the average number of days with migraine reduced 
compared to initial number. In addition, 75% of the patients treated 
with ALD403 experienced a decrease of 50% of migraine days, 
whereas another 44% undergone a decrease of 75% at this same time 
point. Moreover, 16% of the patients in ALD403 indicated in a post-
hoc analysis do not have any migraine attacks in which there’s a 100% 
decline in day of migraine in the entire study period of twelve weeks. 
Nonetheless, placebo group do not show fully decline in migraine days 
if compared to treatment group [52]. Dodick et al., [53] in a single-dose 
and placebo-controlled study demonstrated patients with frequent 
migraine attacks received single dose of eptinezumab by intravenous 
route; where 163 participants aged between 18 and 55 y old with 5 to 
14 migraine were randomly assigned to receive either 1 gm 
eptinezumab or placebo intravenously every 28 d for up to 24 w. In 
which, 57% of the patients from the treatment group experienced mild 
to moderate adverse effects compared to placebo group. Generally, the 
adverse effects were arthralgia, nausea, upper respiratory tract 
infections, fatigue, urinary tract infections, back pain.  
Seven patients from the treatment group and 6 patients from placebo 
experienced upper respiratory tract infections; whereas only 1 patient 
from ALD403 group and 4 patients from placebo had urinary tract 
infections and arthralgia. There is an equal number (n=3) of patients 
from both group noted with from fatigue, 4 and 2 patients experienced 
back pain and nausea respectively. There were 2 patients from 
ALD403 and 1 patient from placebo group experienced serious 
adverse effects. It is undeniable that higher response rates showed in 
ALD403 group with approximately 20% higher than placebo. 
Furthermore, 16% of patients were reported to have no migraine days 
when treated with eptinezumab [54]. 
c) Galcanezumab 
Schuster et al., in their phase two randomized, controlled trial involving 
218 participants with episodic migraine, each participant received a 
subcutaneous 150 mg dose of galcanezumab or a placebo every fortnight 
[55]. The primary endpoint of reduction in monthly migraine headache 
days (MHDs) was achieved during the third month of therapy with a 
monthly decrease of 4.2 and 3.0 MHDs in the treatment and placebo 
group, respectively. The 100% responder rate, defined as absence of 
migraine attacks during the 3-month trial, was also lower in the 
controlled group than in the treatment group [55]. A study by 
Camporeale et al., compared the efficacy of 120 mg and 240 mg of 
galcanezumab, and reported that the overall mean reduction in MHDs 
over 12 mo were 5.6 for 120 mg and 6.5 for 240 mg. Additionally, the 
improved functioning level was observed, and headache-related 
dysfunction was reduced in both dose groups [56]. Subsequently, 
Skjarevski et al., in their randomized, double-blinded, placebo-controlled, 
multicenter, phase 3 study at 109 centers in 11 countries found a 
reduced mean monthly MHDs of 4.3 and 4.2 for 120 mg and 240 mg of 
galcanezumab, respectively [57]. The most recent finding was from a 
phase 3 study conducted by Forderreuther et al., whereby 20% of the 
patients had a sustained response of equal or more than 50% reduction 
of MHDs over six months. Among the 20%, 41% of them maintained the 
said response for three months or more [58]. 
Calcitonin gene-related peptide receptor antagonists 
a) Erenumab 
ARISE [59] was a phase 3 study conducted over 3 mo, in which the 
monthly subcutaneous injections of 70 mg of erenumab vs placebo 
were studied in 577 episodic migraine (EM) patients, and the change 
in MMD as primary outcome was assessed in month 3 of the 
treatment phase. In regards to this end-point, erenumab showed 
more promising results relative to placebo where it showed-2.9 d 
change of MMD from its baseline while placebo group showed-
1.8days change of MMD. This further supports an earlier 
consideration that 70 mg is the minimal effective dose in patients 
with EM [60]. In STRIVE [61], of the same study design as the 
previous trial, 70 mg and 140 mg of erenumab were used. Results 
showed a reduction in MMD of 3.0 d in patients with 70 mg, and 3.5 
d’ reduction with 140 mg, whereas 1.7 d’ reduction in MMD was 
observed in placebo group. Erenumab at both doses elicited a 
change in MMD that was significantly higher by almost 2 d compared 
to placebo. The efficacy of 140 mg Erenumab was higher compared 
to 70 mg and placebo regarding all endpoints. In another phase 3b 
study LIBERTY [62], patients whose previous preventive treatments 
were unsuccessful in EM, and administered with either placebo or 
140 mg of erenumab given in two subcutaneous injections of 70 
mg/1 ml. At week 12, among 119 patients who received erenumab, 
30% of them showed ≥50% decline in the mean number of MMD. 
Meanwhile, in placebo group consisting of 124 patients, only 14% 
showed the same result. Additionally, through weeks 0-4 and weeks 
5-8, relative to placebo group, higher proportion of the erenumab 
group had ≥50% decrease in mean number of MMD. For secondary 
endpoints, erenumab group showed a reduced MMD specifically by 
1.8 d. while placebo reduced 0.2 d in MMD. This further proves 
erenumab as an alternative therapeutic agent in EM patients whom 
other traditional preventive treatments are contraindicated, 
unsuccessful or poorly tolerated.  
In addition to that, another phase 2 trial [63] demonstrated the 
efficacy of treatment with erenumab given in 667 patients suffering 
from chronic migraines. Patients were assigned with either monthly 
subcutaneous placebo, 70 mg or 140 mg of erenumab. Patients 
receiving 70 mg or 140 mg of erenumab demonstrated a significant 
change in MMD of-6.6days for both dose vs placebo at–4.2days. 
Besides, 40% of a group of 188 patients treated with 70 mg 
erenumab and 41% of 187 patients given 140 mg erenumab 
obtained ≥50% reduction in mean number of MMD as compared to 
23% of 281 patients in placebo. Erenumab shows promising efficacy 
in prevention of both chronic as well as EM through various 
demonstrations in both phase 2 and 3 trials. 
Safety 
The safety profiles of conventional antimigraine drugs are compared 
with specific drugs that are exclusively used to block or antagonize 
the receptors. The safety profiles of all old drugs are also compared 
with recently marketed drugs that are used for the treatment of any 
form of migraine. The details are presented here.  
a) Non-steroidal anti-inflammatory drugs 
NSAIDS are known to have gastrointestinal side effects, including 
peptic ulcer, increased risk of myocardial infarction and heart 
failure. The incidence of side effects was proportional to dose [27]. 
b) 5-hydroxy tryptamine (5HT)-agonists 
Triptans are known to have fewer side effects than ergot alkaloids. 
However, cardiovascular disease, which include uncontrolled 
hypertension is a contraindicated factor because triptans also 
vasoconstricts the coronary arteries [29].  
c) Ergots 
Clinical effect of ergots is due to their agonist activity primarily at 5-
HT1B/D receptors and then 5-HT1F receptors to a lesser extent [64]. This 
polypharmacology is believed to contribute to its adverse reactions. 
Side effects of ergots are reflected on their agonism on 5-HT1A 
receptors in which nausea and dysphoria are involved and at 5-HT2A 
receptors that leads to peripheral vasoconstriction. Side effects of 
ergots on cardiovascular activity is then related to its vasoconstrictive 
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actions [32]. Ergots also act on dopamine D2 receptors, presenting 
nausea and vomiting in patients receiving this treatment [64]. Despite 
its inexpensiveness, ergots are associated with tolerability problems, 
potentials of vasoconstriction, poor bioavailability of its oral 
formulations, and risk of medication overuse, and its clinical use is 
relatively less extensive nowadays [33]. 
d) Others drugs: (Botulinum toxin A) 
Most of the studies conducted have shown that Botulinum Toxin A is 
well tolerated by migraine sufferers, with patients exhibiting a 
significantly higher rate of treatment-related adverse effects when 
larger doses of BoNT/A are administered [48]. 
Specific management 
Calcitonin gene-related peptide antagonists 
a) Fremanezumab 
In a study conducted by Dodick et al., at least one adverse event was 
reported by 66% of the participants who were injected with 
fremanezumab monthly at a higher dose compared to 8% who were 
given placebo. The adverse event profile of fremanezumab in this trial 
matches with previously conducted clinical trials, whereby no 
clinically significant patterns of serious adverse events are observed 
[49]. In another phase 2b, double-blind, placebo-controlled, parallel-
group study conducted by Bigal et al., adverse events were reported by 
40% of patients in the placebo group, 53% of patients who received 
675/225 mg dose of fremanezumab and 47% of those who received 
900 mg fremanezumab. The most common adverse events 
experienced were mild injection-site pain and pruritus [50]. Cohen et 
al., conducted two randomized placebo-controlled studies on various 
subcutaneous doses of fremanezumab versus placebo as an add-on-
therapy in episodic migraine and chronic migraine for a period of one 
month. Treatment-emergent adverse events were reported by 44% of 
patients who received placebo and 55% of patients receiving any other 
migraine preventive drug. Serious adverse events were recorded in 
only 2% of patients receiving fremanezumab. It can be concluded that 
fremanezumab is well tolerated with no severe treatment-related 
adverse events and deemed safe for use in migraine sufferers [51]. 
b) Eptinezumab 
A group of 174 patients in the USA assigned to receive either 
treatment (ALD403) or placebo group. Among this, 57% of the 
patients (n=81) in the treatment group and 52% (n=43) in the 
placebo group experienced adverse events. The most frequent 
adverse events were upper respiratory tract infection (URTI), 
urinary tract infection (UTI), fatigue, back pain, arthralgia and 
nausea and vomiting. Six patients from the placebo group and 7 
patients from the treatment group affected with URTI. There was an 
equal proportion of patients suffering from UTI and arthralgia, 
which was 4:1 in both placebo and treatment group. Moreover, there 
was an equal percentage of patients suffering from fatigue in both 
the treatment and placebo group. A 4:3 ratio of the patients was 
having back pain; 2 and 4% of the patients experienced nausea and 
vomiting after receiving placebo and ALD403, respectively. There 
were four serious adverse effects observed in the treatment group, 
while only one adverse effect was noted in the placebo group. 
Nonetheless, among both treatment and placebo group, there was no 
reported significant difference between laboratory safety data or 
vital signs. A-5.6 MMD were reported in the treatment group and-4.6 
MMD for placebo group on the average change in day of migraine 
between baseline and weeks five to eight [52]. 
c) Galcanezumab 
A study by Schuster et al., concluded that injection site reactions 
were more commonly observed in the group treated with 
galcanezumab than the control group. However, the treatment was 
well perceived without major adverse consequences [55]. In 2018, 
the safety and tolerability of galcanezumab were further 
investigated among 135 patients diagnosed with episodic or chronic 
migraine, and the findings revealed that most patients experienced 
treatment-emergent adverse effects (TEAE) include injection site 
reaction, nasopharyngitis, URTI, back pain and sinusitis [56]. 
Calcitonin gene-related peptide receptor antagonists 
a) Erenumab:  
A number of studies have been conducted appraising the safety 
profile of erenumab in the treatment of migraines. The ARISE [59] 
study with 70 mg erenumab reported URTI, whereas LIBERTY [62] 
study showed injection-site pain in its 140 mg intervention arm. 
Another study by Goadsby et al., [61] reported nasopharyngitis as its 
most frequent adverse event (AE) in both 70 mg and 140 mg 
erenumab treatment groups. In a phase 2 study by Tepper et al., [63] 
pain at the injection site was one of the most prominent AEs, 
occurring in 4% of each 70 mg and 140 mg erenumab groups, as well 
as muscle spasm in 4% of patients given with 140 mg erenumab. 
Two serious AEs; traumatic orbital fracture and one incident of 
migraine attack were reported in the group treated with erenumab; 
however, it was assumed that both cases had nothing to do with the 
active drug [62]. Other common AEs include constipation [59, 61], 
nasopharyngitis [61-63], fatigue and sinusitis were also observed. As 
erenumab is of human IgG2 antibody, possibilities in the 
development of neutralizing anti-drug antibodies (ADA) decreases 
[65]. In ARISE, at week 12, 12 out of 279 patients treated with 
erenumab were shown to develop anti-erenumab-binding 
antibodies (AB). At week 4, 1 of the 12 patients showed positive 
neutralizing AB, a, however negative result for the same AB in his 
subsequent visit [59]. Tepper et al., [63] also confirmed that 
occurrence of binding AB in 6% patients of 70 mg group and 2% of 
140 mg group, however, without neutralising AB. There was no 
relationship between this occurrence and AE in this study [63]. 
Incidence of anti-erenumab AB is rare and remit in most of studies. 
Apart from serum chemistry, no notable abnormalities and 
alterations were reported associated to primary vital signs, 
electrocardiogram (ECG) testing, and laboratory monitoring in all 
patients participating in all studies evaluated above [59, 63-65]. In a 
study, only one patient showed abnormal rise in alanine and 
aspartate aminotransferase at week 4 of study; the reading then 
returned to baseline in subsequent visit in week 8 [63]. As erenumab 
does not undergo hepatic metabolism, there were no significant 
impacts on liver enzymes, unlike the hepatotoxicity associated in 
treatment with telcagepant, a small molecule CGRP receptor 
antagonist [66, 67]. There were no deaths reported in studies 
conducted for erenumab [59, 61, 62]. The incidence of AEs in both 
erenumab and placebo interventions were similar [59, 61-65] and 
this further confirms the safety of the administration of erenumab. 
Erenumab is preferred as migraine preventive treatment with 
positive efficacy and safety profile, contributed by its 
pharmacokinetics [38]. 
CONCLUSION 
All the existing antimigraine therapies were included for comparison 
of efficacy and safety in controlling repetitive migraine attack. Upon 
comparison, there are four migraine prevention drugs were 
considered more effective in terms of controlling the severity and 
frequency of migraine attack; there are Fremanezumab, 
Eptinezumab, Galcanezumab and Erenumab. Among these, 
Erenumab, a CGRP receptor antagonists at a dose of 70 and 140 mg 
was found to be most effective in controlling the frequency of 
migraine episodes. Erenumab may be a suitable alternative 
therapeutic agent in EM patients whom other traditional preventive 
treatments are contraindicated, unsuccessful or poorly tolerated as 
it produces more than 50 percent reduction in mean number of 
MMD in just few weeks of therapy. 
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